AnaptysBio Inc (ANAB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.54 is considered Undervalued compared with the five-year average of -4.34. The fair price of AnaptysBio Inc (ANAB) is between 563.44 to 819.61 according to relative valuation method. Compared to the current price of 54.91 USD , AnaptysBio Inc By Undervalued By 90.25%.

Relative Value

Fair Zone

563.44-819.61

Current Price：54.91

90.25%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is AnaptysBio Inc (ANAB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

AnaptysBio Inc (ANAB) has a current Price-to-Book (P/B) ratio of -42.14. Compared to its 3-year average P/B ratio of 11.83, the current P/B ratio is approximately -456.14% higher. Relative to its 5-year average P/B ratio of 7.80, the current P/B ratio is about -640.28% higher. AnaptysBio Inc (ANAB) has a Forward Free Cash Flow (FCF) yield of approximately -11.68%. Compared to its 3-year average FCF yield of -17.79%, the current FCF yield is approximately -34.38% lower. Relative to its 5-year average FCF yield of -12.68%, the current FCF yield is about -7.94% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ANAB competitors is 362.73, providing a benchmark for relative valuation. AnaptysBio Inc Corp (ANAB.O) exhibits a P/S ratio of 8.54, which is -97.65% above the industry average. Given its robust revenue growth of 154.26%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ANAB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ANAB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ANAB currently overvalued or undervalued?

What is AnaptysBio Inc (ANAB) fair value?

ANAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of AnaptysBio Inc (ANAB) is between 563.44 to 819.61 according to relative valuation method.

How does ANAB's valuation metrics compare to the industry average?

The average P/S ratio for ANAB's competitors is 362.73, providing a benchmark for relative valuation. AnaptysBio Inc Corp (ANAB) exhibits a P/S ratio of 8.54, which is -97.65% above the industry average. Given its robust revenue growth of 154.26%, this premium appears sustainable.

What is the current P/B ratio for AnaptysBio Inc (ANAB) as of Mar 03 2026?

As of Mar 03 2026, AnaptysBio Inc (ANAB) has a P/B ratio of -42.14. This indicates that the market values ANAB at -42.14 times its book value.

What is the current FCF Yield for AnaptysBio Inc (ANAB) as of Mar 03 2026?

As of Mar 03 2026, AnaptysBio Inc (ANAB) has a FCF Yield of -11.68%. This means that for every dollar of AnaptysBio Inc's market capitalization, the company generates -11.68 cents in free cash flow.

What is the current Forward P/E ratio for AnaptysBio Inc (ANAB) as of Mar 03 2026?

As of Mar 03 2026, AnaptysBio Inc (ANAB) has a Forward P/E ratio of -20.48. This means the market is willing to pay $-20.48 for every dollar of AnaptysBio Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for AnaptysBio Inc (ANAB) as of Mar 03 2026?

As of Mar 03 2026, AnaptysBio Inc (ANAB) has a Forward P/S ratio of 8.54. This means the market is valuing ANAB at $8.54 for every dollar of expected revenue over the next 12 months.

ANAB Valuation